Commodore Capital LP Invests $42.81 Million in Terns Pharmaceuticals, Inc. $TERN

Commodore Capital LP bought a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,700,000 shares of the company’s stock, valued at approximately $42,807,000. Terns Pharmaceuticals comprises about 2.1% of Commodore Capital LP’s holdings, making the stock its 18th biggest holding. Commodore Capital LP owned approximately 0.06% of Terns Pharmaceuticals as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Terns Pharmaceuticals by 5.9% in the third quarter. Vanguard Group Inc. now owns 4,559,917 shares of the company’s stock valued at $34,245,000 after purchasing an additional 253,751 shares during the last quarter. Candriam S.C.A. increased its stake in Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after buying an additional 214,266 shares during the last quarter. Geode Capital Management LLC lifted its position in Terns Pharmaceuticals by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock worth $6,094,000 after buying an additional 59,145 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth about $4,774,000. Finally, Franklin Resources Inc. bought a new position in shares of Terns Pharmaceuticals in the 2nd quarter valued at about $4,765,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Terns Pharmaceuticals Price Performance

Shares of Terns Pharmaceuticals stock opened at $46.52 on Friday. Terns Pharmaceuticals, Inc. has a 1 year low of $1.87 and a 1 year high of $48.26. The company has a market capitalization of $4.83 billion, a price-to-earnings ratio of -45.17 and a beta of -0.31. The business has a fifty day simple moving average of $38.76 and a two-hundred day simple moving average of $26.24.

Insider Activity

In other news, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $39.19, for a total value of $571,507.77. Following the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at approximately $11,324,969.44. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 155,826 shares of company stock valued at $5,882,597 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TERN has been the subject of several recent research reports. Citizens Jmp increased their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a research report on Thursday, December 11th. Jefferies Financial Group reissued a “buy” rating and issued a $70.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. BMO Capital Markets raised their target price on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Wall Street Zen raised shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $58.11.

Terns Pharmaceuticals Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.